ライフサイエンスコーパス: ABI

1 ABI and CVD risk factors were measured at Visit 2 (1990

2 ABI values from each subject's earliest vascular laborat

3 ABI-007 demonstrated significantly higher response rates

4 ABI-007 is a novel nanoparticle, albumin-bound paclitaxe

5 ABI-1, a downstream target of Abl non-receptor tyrosine

6 ABI-III analogues maintain their mechanisms of action by

7 ABI-III compounds are highly potent against a panel of m

8 ell's C statistic (0.74 vs. 0.76; p = 0.04); ABI, hsCRP levels, and FH produced no improvement in Har

9 The proportion of patients with > or =1 ABI value < or =0.9, indicating obstructed lower limb ar

10 t and isolated Abelson-interactor protein-1 (ABI-1).

11 0B interacts with Abl-interacting protein-1 (ABI-1)/Abi1, a component of the WAVE complex, to organiz

12 p140/PIR121, GEX-3/NAP1/HEM2/KETTE, or ABI-1/ABI, the three other components of the C. elegans WAVE/S

13 From 1995 to 1998, ABI was measured in 1,097 men and 1,189 women (mean age

14 (RR: 1.9) at 6 years, independent of Visit 2 ABI and other risk factors.

15 e cases, low (0.70 < or = ABI <0.90) Visit 2 ABIs were associated with significantly elevated all-cau

16 Both a low (<1.00) and a high (>/=1.40) ABI were associated with incident CVD events.

17 w normal ABI (1.00 to 1.09), and normal ABI (ABI 1.10 to 1.30).

18 han traditional risk factors and an abnormal ABI.

19 ound to be reduced in subjects with abnormal ABI, manifesting in prolonged recovery during the early

20 Abnormal ABIs, both low and high, are associated with elevated ca

21 The implementation of an alternative ABI method and use of the brachial difference identifies

22 Of those remaining, an alternative ABI method using the lower of the 2 ankle pressures assi

23 An ABI 1.00 to 1.30 was considered normal, PAD was defined

24 An ABI dependence was found in both PHF (p = 0.04) and TTP

25 -exercise ABI </=0.90, and PCA defined as an ABI >/=1.4 and/or an ankle systolic blood pressure >255

26 PAD was defined as an ABI less than 0.90.

27 A total of 296 subjects had an ABI >or=1.40 in at least 1 leg, and 4,420 had an ABI bet

28 >or=1.40 in at least 1 leg, and 4,420 had an ABI between 0.90 and 1.40.

29 from a community health registry, and had an ABI screening test.

30 tion with 157 nm light was implemented in an ABI model 4700 matrix-assisted laser desorption ionizati

31 rachial index (ABI) at rest and typically an ABI </= 0.90 is used to define LE-PAD.

32 c digest protein standards analyzed using an ABI 4700 MALDI TOFTOF mass spectrometer, and a free, ope

33 stem confirmed the interaction of MIG-10 and ABI-1 and showed that it requires the SH3 domain of ABI-

34 These results suggest that MIG-10 and ABI-1 interact physically to promote cell migration and

35 our results suggest that MIG-10, UNC-53, and ABI-1 act sequentially to mediate excretory cell process

36 t PAD cases were identified for ABI <0.9 and ABI >1.4, respectively.

37 Although only 12% of the ABA- and ABI-dependent transcriptional targets were induced by bo

38 We obtained CCT and ABI measurements in 588 RA patients.

39 on the SmartCycler II, ABI 7500 Fast DX, and ABI QuantStudio DX instruments compared to CCNA were 90.

40 ears of age and measured kidney function and ABI.

41 d based on our previously reported ABI-I and ABI-II analogues.

42 ation in men and with common carotid IMT and ABI in women (all P<0.05) after adjustment for model 1 v

43 0.34) and -0.22 (SE 0.35), respectively] and ABI after exercise [-0.29 (SE 0.34) and -0.30 (0.35), re

44 significant changes in iCIMT, CAC score, and ABI were not observed.

45 ata from the Roche 454, Illumina/Solexa, and ABI SOLiD platforms typically present shorter read lengt

46 s pedis artery or posterior tibial artery) ("ABI-LO"), 2) with the highest ankle pressure ("ABI-HI"),

47 cess coronary and carotid atherosclerosis at ABI values below 1.10 (men) and 1.00 (women) and may imp

48 The mean baseline ABI in all patients was 0.71, 76.6% of the patients had

49 ared with persons who have a normal baseline ABI.

50 ed with ABI change independently of baseline ABI and cardiovascular disease risk factors.

51 anges at 12 years, independently of baseline ABI, cardiovascular risk factors, and baseline cardiovas

52 ycler 480 system and the Applied Biosystems (ABI) 7500 real-time PCR system.

53 HR: 3.22 (95% CI: 1.43 to 7.21); borderline ABI, HR: 3.07 (95% CI: 1.21 to 7.84); and low normal ABI

54 women (2.85 (definite PAD), 1.27 (borderline ABI), 1.11 (low-normal ABI), 1.00 (normal ABI; referent)

55 d men (3.26 (definite PAD), 1.72 (borderline ABI), 1.14 (low-normal ABI), 1.00 (normal ABI; referent)

56 69), mild PAD (ABI 0.70 to 0.89), borderline ABI (0.90 to 0.99), low normal ABI (1.00 to 1.09), and n

57 terial disease (PAD)), 0.90-0.99 (borderline ABI), 1.00-1.09 (low-normal ABI), 1.10-1.29 (normal ABI)

58 At 5-year follow-up, persons with borderline ABI values have a higher incidence of mobility loss and

59 transcriptional targets were induced by both ABI factors in 11 day old plants, 40% of those normally

60 correlate with disease state as measured by ABI and demonstrate preserved microvascular flow reserve

61 rior tibial arteries, the authors calculated ABI in 3 ways: 1) with the lowest ankle pressure (dorsal

62 In the excretory canal, ABI-1 is thought to act downstream of UNC-53/NAV2, linki

63 , but homology to a previously characterized ABI Five Binding Protein (AFP).

64 the tonotopic frequency gradients of the CN, ABIs improve speech understanding to varying degrees.

65 .0 or LGPL 2.1 license at https://github.com/ABI-Software-Laboratory/ICMA and a standalone virtual ma

66 usting for age, gender, race, comorbidities, ABI, and other confounders, participants in the poorest

67 Continuous ABI and PAD (ABI </=0.9) phenotypes adjusted for age and

68 Analyses were performed on normalized crude ABI and on normalized residuals from multiple linear reg

69 Current ABI protocols might need to be evaluated.

70 Patients with decreasing ABI may be candidates for more intensive cardiovascular

71 on or stenoses, peripheral arterial disease (ABI <1.0), symptomatic cardiac disease, unrelated causes

72 DCN) contributes to patients' hearing during ABI stimulation.

73 ectively, for incident PAD defined as either ABI <0.9 or ABI >1.4.

74 The authors sought to estimate ABI heritability in a community-based sample.

75 AD was defined as a resting or post-exercise ABI </=0.90, and PCA defined as an ABI >/=1.4 and/or an

76 Five ABI categories were defined: <0.90 (definite peripheral

77 5% confidence interval (CI): 0.32, 1.01) for ABI <0.9 and 2.24 (95% CI: 1.01, 4.32) for ABI >1.4.

78 r ABI <0.9 and 2.24 (95% CI: 1.01, 4.32) for ABI >1.4.

79 No other SNP associations for ABI or PAD achieved genome-wide significance.

80 Mutations in genes for ABI domain proteins, designated spdA, spdB and spdC (sur

81 d 206 incident PAD cases were identified for ABI <0.9 and ABI >1.4, respectively.

82 de 4 neutropenia was significantly lower for ABI-007 compared with standard paclitaxel (9% v 22%, res

83 We noted a similar pattern for ABI values >1.3, indicative of arterial incompressibilit

84 ture, has been considered a logic target for ABI stimulation, it is not yet clear how the dorsal coch

85 d interleukin-6 at baseline had the greatest ABI decline.

86 duals assigned to the traditional-PAD group (ABI <0.90) with the traditional ABI method.

87 High ABI is associated with greater LV mass; an association t

88 High ABI might lead to greater LV mass through nonatheroscler

89 1.10-1.29 (normal ABI), and > or =1.30 (high ABI).

90 1.00 (normal ABI; referent), and 1.43 (high ABI); p for trend = 0.0002).

91 1.00 (normal ABI; referent), and 0.78 (high ABI); p for trend = 0.0002) and men (3.26 (definite PAD)

92 001) for a low and 1.85 (p=0.050) for a high ABI after adjustment for both traditional and newer biom

93 Individuals with a high ABI have higher odds for foot ulcers and neuropathy, as

94 In humans, a high ABI indicates stiff peripheral arteries and is associate

95 In this study, both a low and a high ABI were associated with elevated CVD risk in persons fr

96 A high ABI, a marker of lower extremity arterial stiffness, is

97 rence were positively associated with a high ABI, and smoking and dyslipidemia were inversely associa

98 n, 0.4), 6% had a low ABI, and 5% had a high ABI.

99 ad CKD, 13% had a low ABI, and 3% had a high ABI.

100 idemia were inversely associated with a high ABI.

101 nterval [CI]: 1.6 to 2.5; p <0.001) and high ABI (RR: 1.6; 95% CI: 1.0 to 2.3; p = 0.03).

102 The association between CKD and high ABI is unknown.

103 1) and a 1.4-fold greater prevalence of high ABI (95% CI: 1.0, 1.9; P = 0.03) in models adjusted for

104 84 to 3.33), whereas the association of high ABI was minimally altered (6.01 g/m(2) higher, 95% confi

105 % confidence interval: 0.65 to 4.75) or high ABI (6.84 g/m(2) higher, 95% confidence interval: 3.2 to

106 ccounting for multiple comparisons, the high ABI group had significantly higher odds for foot ulcers

107 usting for patients with other CVD, the high ABI group scored 2.0 points lower on the physical compon

108 Whether high ABI is associated with LV mass in humans and whether thi

109 ver, the association of phosphorus with high ABI differed by chronic kidney disease (CKD) status (in

110 th low ABI and are also associated with high ABI in persons with CKD.

111 han 20 decreased across progressively higher ABI categories in both women (2.85 (definite PAD), 1.27

112 We have recently identified ABI family, member 3 (NESH) binding protein (Abi3bp) as

113 ity of the Lyra assay on the SmartCycler II, ABI 7500 Fast DX, and ABI QuantStudio DX instruments com

114 ity of the Lyra assay on the SmartCycler II, ABI 7500, and QuantStudio instruments were 82.1% and 96.

115 viously reported 2-aryl-4-benzoyl-imidazole (ABI) derivatives.

116 Auditory brainstem implants (ABIs) restore hearing by electrical stimulation of the c

117 ssociated favorably with common carotid IMT, ABI, and coronary artery calcification in men and with c

118 ning, statin use/non-use, ABI, and change in ABI, the PAD participants using statins had less annual

119 Decreases in ABI of more than 0.15 between Visit 1 and Visit 2 were s

120 A modest proportion of the variability in ABI is explained by genetic factors.

121 Genetic contributions to variation in ABI are largely unknown.

122 Measurements included ABI, carotid artery intima-media thickness, and coronary

123 .90) and high (> or =1.40 or incompressible) ABI as compared with intermediate ABI in 5,330 older US

124 w (<0.90) and high (>1.40 or incompressible) ABI with LV mass by cardiac magnetic resonance imaging (

125 These factors were associated with increased ABI (P<0.05) in women only.

126 For all 3 methods, the index ABI was the lower of the ABIs calculated from the left a

127 is to determine if an ankle-brachial index (ABI) >or=1.40 is associated with reduced quality of life

128 men and women with an ankle brachial index (ABI) <0.90 and 212 with ABI 0.90 to 1.50.

129 measurement of the ankle-to-brachial index (ABI) and CASL.

130 d associations between ankle-brachial index (ABI) and subclinical atherosclerosis in the Multi-Ethnic

131 to those with a normal ankle-brachial index (ABI) and those with peripheral arterial disease (PAD).

132 on the use of resting ankle-brachial index (ABI) as a screening test for PAD or as a risk predictor

133 assessed by computing ankle brachial index (ABI) at baseline (1,582 participants) and after 12 years

134 nosis of LE-PAD is the ankle-brachial index (ABI) at rest and typically an ABI </= 0.90 is used to de

135 use of an alternative ankle-brachial index (ABI) calculation method improves mortality risk predicti

136 A low ankle brachial index (ABI) indicates atherosclerosis and an increased risk of

137 l artery disease as an ankle brachial index (ABI) lower than or equal to 0.90.

138 isease (CKD) with high ankle brachial index (ABI) measurement and to compare its strength with that o

139 he association of high ankle brachial index (ABI) measurements with left ventricular (LV) mass, and t

140 ligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascula

141 The ankle-brachial index (ABI) provides information on both atherosclerosis and ar

142 derline and low normal ankle-brachial index (ABI) values with functional decline over a 5-year follow

143 both a low and a high ankle-brachial index (ABI) with incident cardiovascular events in a multiethni

144 ts associated with the ankle-brachial index (ABI), a noninvasive measure of PAD, we conducted a meta-

145 d by low values of the ankle-brachial index (ABI), and future CVD risk has been demonstrated.

146 circulating PC levels, ankle brachial index (ABI), and walking impairment questionnaire (WIQ) and 36-

147 Ankle-brachial index (ABI), coronary artery calcification, and internal and co

148 ma media thickness and ankle-brachial index (ABI), for N = 549.

149 lcium (CAC) score, the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) levels

150 e ratio, also known as ankle-brachial index (ABI), in RA patients.

151 re and incident PAD by ankle brachial index (ABI).

152 ods of calculating the ankle-brachial index (ABI).

153 y independently of the ankle brachial index (ABI).

154 tation better than the ankle-brachial index (ABI).

155 shed by the use of the ankle-brachial index (ABI).

156 re (CAC score, >0), or ankle-brachial index (ABI, <0.90).

157 The ankle-brachial blood pressure index (ABI) is a widely utilized measure for detecting peripher

158 cts (YH) (n = 10; mean ankle-brachial index [ABI] 1.0 +/- 0.1, mean age 30 +/- 7 years); 2) periphera

159 D] claudication distances, pressure indices [ABI], popliteal artery flow, and QOL with the short-form

160 membrane proteins with abortive infectivity (ABI) domains, elements first described in lactococci for

161 g the transcription factors ABA insensitive (ABI)4 and ABI5.

162 actors, including abscisic acid-insensitive (ABI)3 and ABI5, are known to control this developmental

163 ependent inactivation of the ABA-insensitive(ABI)-clade protein phosphatases(PP)2Cs, thereby permitti

164 pressible) ABI as compared with intermediate ABI in 5,330 older US men, among whom the mean serum pho

165 Compared with subjects with intermediate ABI, LV mass was higher with either low (2.70 g/m(2) hig

166 Intermediate ABIs served as the reference category.

167 irradiation (TBI) and abdominal irradiation (ABI) models to demonstrate a very limited, if any, role

168 Of those, 3350 with a low ABI (< or = 0.95) were entered into the trial, which was

169 ardiovascular disease, identified with a low ABI based on screening a general population, the adminis

170 Screening for a low ABI can identify an asymptomatic higher risk group poten

171 513 participants, 23% had CKD, 13% had a low ABI, and 3% had a high ABI.

172 g/dL (standard deviation, 0.4), 6% had a low ABI, and 5% had a high ABI.

173 are its strength with that of CKD with a low ABI.

174 tin C-based CKD was associated with both low ABI (relative risk [RR]: 2.0; 95% confidence interval [C

175 events in persons with a screen-detected low ABI but may have increased the risk for major bleeding e

176 ed with a 1.6-fold greater prevalence of low ABI (95% confidence interval (CI): 1.2, 2.1; P < 0.001)

177 stantially attenuated the association of low ABI with LV mass index (1.24 g/m(2) higher, 95% confiden

178 and to compare its strength with that of low ABI with LV mass.

179 er phosphorus levels are associated with low ABI and are also associated with high ABI in persons wit

180 rterial disease (PAD) patients (n = 12; mean ABI 0.6 +/- 0.1, mean age 71 +/- 9 years); and 3) age-ma

181 healthy control subjects (AHC) (n = 8; mean ABI 1.1 +/- 0.1, mean age 68 +/- 9 years).

182 The mean ABI was 1.1 (range, 0.4-1.4).

183 ean ancestry ( approximately 60% women, mean ABI 1.02 to 1.19), including 3409 participants with PAD

184 d should be further pursued in designing new ABIs.

185 ne ABI), 1.11 (low-normal ABI), 1.00 (normal ABI; referent), and 0.78 (high ABI); p for trend = 0.000

186 ne ABI), 1.14 (low-normal ABI), 1.00 (normal ABI; referent), and 1.43 (high ABI); p for trend = 0.000

187 .00-1.09 (low-normal ABI), 1.10-1.29 (normal ABI), and > or =1.30 (high ABI).

188 oor survival, worse than those with a normal ABI or those with PAD.

189 d to have ischemic leg pain; thus, a "normal ABI" is likely to range from 1.00 to 1.39.

190 loss compared with persons who have a normal ABI.

191 ), low normal ABI (1.00 to 1.09), and normal ABI (ABI 1.10 to 1.30).

192 tudy period was 88%, 70%, and 60% for normal ABI, PAD, and PCA, respectively.

193 .8 +/- 13.0 years, 59% male); 29% had normal ABI, 54% had PAD, and 17% had PCA.

194 ), borderline ABI (0.90 to 0.99), low normal ABI (1.00 to 1.09), and normal ABI (ABI 1.10 to 1.30).

195 A low normal ABI is associated with an increased incidence of mobilit

196 he associations of borderline and low normal ABI with functional decline are unknown.

197 3.07 (95% CI: 1.21 to 7.84); and low normal ABI, HR: 2.61 (95% CI: 1.08 to 6.32; p trend = 0.0018).

198 AD), 1.27 (borderline ABI), 1.11 (low-normal ABI), 1.00 (normal ABI; referent), and 0.78 (high ABI);

199 AD), 1.72 (borderline ABI), 1.14 (low-normal ABI), 1.00 (normal ABI; referent), and 1.43 (high ABI);

200 0.99 (borderline ABI), 1.00-1.09 (low-normal ABI), 1.10-1.29 (normal ABI), and > or =1.30 (high ABI).

201 ts in persons with borderline and low-normal ABI.

202 nd 1.3 (1.2 to 1.4) compared with the normal ABI and PAD groups, respectively.

203 Legs with low-normal and high-normal ABIs appeared to have ischemic leg pain; thus, a "normal

204 iable-adjusted heritabilities for normalized ABI estimated using variance-components analysis were 0.

205 pair correlation coefficients for normalized ABI were 0.15 and 0.11, respectively, resulting in herit

206 Novel ABI-III compounds were designed and synthesized based on

207 a Assembler was modified for combinations of ABI 3730 and 454 FLX reads.

208 re treated with an average of five cycles of ABI-007; 33% of patients received > or = six cycles of t

209 nd showed that it requires the SH3 domain of ABI-1.

210 d with both the high and the low extremes of ABI in community-living older people.

211 were computed and assessed as a function of ABI and calf muscle group.

212 The heritability of ABI was estimated using variance-components methods in S

213 eening method; the diagnostic performance of ABI testing in primary care populations, unselected popu

214 s associated with a 2-fold increased risk of ABI >1.4 (hazard ratio = 2.04, 95% CI: 1.02, 3.41).

215 ng superior efficacy and reduced toxicity of ABI-007 compared with standard paclitaxel.

216 tomatic populations; the predictive value of ABI testing for major CVD outcomes in primary care or un

217 r incident PAD defined as either ABI <0.9 or ABI >1.4.

218 /Sra1/p140/PIR121, GEX-3/NAP1/HEM2/KETTE, or ABI-1/ABI, the three other components of the C. elegans

219 sequence data files produced by MegaBace or ABI sequencers as well as Staden SCF trace files and pla

220 ned by cCIMT but not by iCIMT, CAC score, or ABI.

221 (<0.70) and, in some cases, low (0.70 < or = ABI <0.90) Visit 2 ABIs were associated with significant

222 Continuous ABI and PAD (ABI </=0.9) phenotypes adjusted for age and sex were exa

223 , moderate PAD (ABI 0.50 to 0.69), mild PAD (ABI 0.70 to 0.89), borderline ABI (0.90 to 0.99), low no

224 llows: severe PAD (ABI <0.50), moderate PAD (ABI 0.50 to 0.69), mild PAD (ABI 0.70 to 0.89), borderli

225 Progressive PAD (ABI decline >0.15) was significantly and independently a

226 nts were categorized as follows: severe PAD (ABI <0.50), moderate PAD (ABI 0.50 to 0.69), mild PAD (A

227 in polymerization, similar to their parental ABI analogues.

228 In particular, ABI's sequencer (SOLiD system) poses a big computational

229 and safe approach for the treatment of post-ABI tremor in the largest series published at the time o

230 ries of eight consecutive patients with post-ABI tremor were treated with DBS of the ventro-oralis po

231 etter ICD, ACD, and resting and postexercise ABI (P < 0.01) than Group 2.

232 12 median ICD, ACD, resting and postexercise ABI had increased by 197%, 212%, 17%, and 64%, respectiv

233 I-LO"), 2) with the highest ankle pressure ("ABI-HI"), and 3) with the mean of the ankle pressures ("

234 nd 3) with the mean of the ankle pressures ("ABI-MN").

235 aryl group and the benzoyl group of previous ABI structures and were named as reverse ABI (RABI) anal

236 lengths generated in Applied Biosystems(R) (ABI) either manually or automatically by providing panel

237 synthesized based on our previously reported ABI-I and ABI-II analogues.

238 The review focused on resting ABI as the sole screening method; the diagnostic perform

239 ous ABI structures and were named as reverse ABI (RABI) analogues.

240 However, in mice treated with DEX and Scl-ABI, a significant increase in trabecular bone at the fe

241 CAC score, ABI, and FH were independent predictors of ASCVD events

242 CAC score, ABI, and FH were independent predictors of ASCVD events.

243 the colchicine binding site based on SMART, ABI, and PAT templates, we have designed, synthesized, a

244 stic significance of declining versus stable ABI has not been studied.

245 -Agilent] and the 7500 real-time PCR system [ABI Life Technologies]).

246 iable logistic regression models showed that ABI was a strong correlate of pain category throughout t

247 The ABI is used to diagnose peripheral arterial disease (PAD

248 The ABI was calculated at baseline in 1,413 study participan

249 The ABI was categorized as low (<0.90), low-normal (0.90 to

250 Adding the ABI to the FRS probably has limited value for predicting

251 allelic discrimination Taqman assay and the ABI 7900HT Sequence Detection System (v2.1) was used to

252 nd newer biomarker CVD risk factors, and the ABI significantly improved risk discrimination.

253 ustment for traditional risk factors and the ABI.

254 ntitis based on AL and PAD determined by the ABI (odds ratio = 8.18).

255 zed fingerprinting profiles generated by the ABI Genetic Analyzers.

256 persons with PAD beyond that provided by the ABI.

257 nd on the ankle pressure used to compute the ABI.

258 sized fragment information directly from the ABI raw trace files, or from data files exported from Ge

259 There were no significant differences in the ABI, WIQ distance and speed scores, claudication onset t

260 3 sensory neuropathy was more common in the ABI-007 arm than in the standard paclitaxel arm (10% v 2

261 d measures of subclinical CVD, including the ABI.

262 ress the cost effectiveness of measuring the ABI in targeted population groups.

263 e men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization.

264 All sites performed the ABI using a Doppler device and a standardized technique.

265 re genotyped at 400 markers representing the ABI PRISM linkage map MD-10, and at the HLA-B, DRB1, DQA

266 e excretory cell canals, suggesting that the ABI-1/MIG-10 interaction is relevant in vivo.

267 To address the hypothesis that the ABI-clade PP2Cs regulate the bZIPs directly, in addition

268 ng correlate of pain category throughout the ABI range.

269 Traditionally, the ABI is calculated with the higher of the dorsalis pedis

270 nucleotide polymorphism rs12979860 using the ABI TaqMan allelic discrimination kit.

271 s1127354 and rs7270101 were tested using the ABI TaqMan kit.

272 trol samples when RNA was isolated using the ABI Tempus method, but not using the PAXgene method (p <

273 itude of the NRI was probably small when the ABI was added to the FRS to predict CAD or CVD events.

274 ing for PAD and CVD risk assessment with the ABI in adults.

275 methods, the index ABI was the lower of the ABIs calculated from the left and right legs.

276 ratios (HRs) for mobility loss according to ABI category were as follows: severe PAD, HR: 4.16 (95%

277 In addition to ABI, several risk variables were independent correlates

278 l-PAD group (ABI <0.90) with the traditional ABI method.

279 ty who are currently missed with traditional ABI methods.

280 better understand the mechanisms underlying ABIs, we tested if electrical stimulation of the rat DCN

281 evious year functioning, statin use/non-use, ABI, and change in ABI, the PAD participants using stati

282 e magnitudes of association were found using ABI-LO.

283 ression of 15-LOX-1 was quantified utilizing ABI prism real-time quantitative RT-PCR.

284 Valid ABI measurements were obtained on 1582, 1081, and 813 pa

285 This study demonstrated that weekly ABI-007 can be administered at doses exceeding those typ

286 al atherosclerosis and CVD risk factors when ABI-HI was used, except when risk estimates for PAD were

287 r in women and 2.74 times higher in men when ABI-LO was used.

288 nkle brachial index (ABI) <0.90 and 212 with ABI 0.90 to 1.50.

289 nificant association on chromosome 9p21 with ABI.

290 sed arsenic methylation were associated with ABI >1.4 but not with ABI <0.9.

291 r = 0.05) were significantly associated with ABI change independently of baseline ABI and cardiovascu

292 coronary artery disease are associated with ABI.

293 coronary artery disease were associated with ABI: DAB21P (rs13290547, P=3.6x10(-5)), CYBA (rs3794624,

294 ar CDKN2B had the strongest association with ABI (beta=-0.006, P=2.46x10(-8)).

295 e used to test each SNP for association with ABI and PAD using additive genetic models.

296 sed to evaluate the associations of CKD with ABI categories.

297 examination: 2000-2002), in comparison with ABI-HI, the relative prevalence of PAD was 3.95 times hi

298 zero, except for hepcidin and ferritin with ABI at rest [-0.27 (SE 0.34) and -0.22 (SE 0.35), respec

299 n were associated with ABI >1.4 but not with ABI <0.9.

300 with progressive atherosclerosis at 5 years (ABI change from baseline), and CRP (P< or =0.01), IL-6 (